RxDoctor Payments Data

Thiri Myint, MD

Internal Medicine · Jackson Hts, NYNPI 1629486519

Payments from drug & device makers

$2,220in general payments, 2019–2025

Across 83 payments — averaging $26.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$575
  • Esperion Therapeutics, Inc.$247
  • Lilly USA, LLC$234
  • AbbVie$211
  • Boehringer Ingelheim$177
  • IBSA Pharma Inc.$135
  • plus $641 from 11 others

What the payments were for

  • Food & beverage$2,220100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,220 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$15,234
Medicare patients
45
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol63$62,962
JardianceEmpagliflozin74$58,491
VemlidyTenofovir Alafenamide32$45,777
Diclofenac Sodium141$25,779
OzempicSemaglutide17$17,978
JanuviaSitagliptin Phosphate20$17,405
LinzessLinaclotide12$6,768
TradjentaLinagliptin12$6,764
VascepaIcosapent Ethyl13$5,095
Dexlansoprazole DrDexlansoprazole20$4,506
Bepotastine Besilate23$4,407
ArexvyRsvpref3 Antigen/As01e/Pf14$3,880
Fenofibrate14$3,717
ShingrixVaricella-Zoster Ge/As01b/Pf21$3,058
Atorvastatin Calcium252$2,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$177$65,25586 claims
AstraZenecaFarxiga$575$62,96263 claims
Novo NordiskOzempic$115$17,97817 claims
AbbVieLinzess, Synthroid$211$8,15323 claims
GSKArexvy, Shingrix$104$6,93735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Jackson Hts

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →